Sponsor & Developer Portfolio

Pfizer

Clinical development pipeline, platform architecture, and registered trial tracking for Pfizer vaccine candidates.

Candidates

Target Diseases

Linked Studies

Development Phase Distribution

Discontinued / Inactive: 9 Phase 3 Clinical Trial: 4 Phase 2 Clinical Trial: 2 Phase 1 Clinical Trial: 2 Approved / Licensed: 1

Platform Technologies

Biological (unspecified platform): 13 Protein subunit (OspA): 1 See FDA product page / label: 1 Conjugate vaccine: 1 mRNA: 1 DNA: 1

Target Pathogens & Indications

Alzheimer Disease Alzheimer's Disease Clostridioides Difficile Associated Disease Clostridoides Difficile Associated Disease HIV Influenza Lyme disease Meningococcal disease Pneumococcal disease Prostatic Neoplasms RSV Staphylococcal Vaccine

Vaccine Pipeline Candidates (18)

Detailed candidate profiles, clinical phases, target indications, and anticipated milestones.

View Global Pipeline Matrix →

Approved / Licensed fda-abrysvo

ABRYSVO

Target: RSV

Platform: See FDA product page / label

Key Milestone: US-licensed — see product label / ACIP for use; further supplements may expand indication

View Full Clinical Profile → Disease Hub →

Discontinued / Inactive ctgov-acc-001-pfizer

ACC-001

Target: Alzheimer's Disease

Platform: Biological (unspecified platform)

Key Milestone: Primary completion (most advanced trial): 2013-12 (registry estimate)

View Full Clinical Profile →

Discontinued / Inactive ctgov-acc-001-qs21-3mcg-pfizer

ACC-001+ QS21 (3mcg)

Target: Alzheimer Disease

Platform: Biological (unspecified platform)

Key Milestone: Primary completion (most advanced trial): 2013-12 (registry estimate)

View Full Clinical Profile →

Discontinued / Inactive ctgov-menabcwy-pfizer

Bexsero

Target: Meningococcal disease

Platform: Biological (unspecified platform)

Key Milestone: Primary completion (most advanced trial): 2022-09-15 (registry estimate)

View Full Clinical Profile → Disease Hub →

Discontinued / Inactive ctgov-hiv-1-gag-dna-formulated-with-bupivacaine-wyeth-is-now-a-wholly-

IL-15 DNA (formulated with bupivacaine)

Target: HIV

Platform: DNA

Key Milestone: See linked ClinicalTrials.gov records for primary completion dates

View Full Clinical Profile →

Discontinued / Inactive ctgov-pf-06755992-pfizer

PF-06755992

Target: Prostatic Neoplasms

Platform: Biological (unspecified platform)

Key Milestone: Primary completion (most advanced trial): 2021-02-23 (registry estimate)

View Full Clinical Profile →

Discontinued / Inactive ctgov-pneumo-23-wyeth-is-now-a-wholly-owned-subsidiary-of-pfizer

Pneumo 23

Target: Pneumococcal disease

Platform: Conjugate vaccine

Key Milestone: See linked ClinicalTrials.gov records for primary completion dates

View Full Clinical Profile → Disease Hub →

Discontinued / Inactive ctgov-multivalent-pfizer

Prevnar 13

Target: Pneumococcal disease

Platform: Biological (unspecified platform)

Key Milestone: Primary completion (most advanced trial): 2020-11-05 (registry estimate)

View Full Clinical Profile → Disease Hub →

Discontinued / Inactive ctgov-staphylococcus-aureus-4-antigen-sa4ag-vaccine-pfizer

Staphylococcus aureus 4-Antigen (SA4Ag) Vaccine

Target: Staphylococcal Vaccine

Platform: Biological (unspecified platform)

Key Milestone: Primary completion (most advanced trial): 2019-06-26 (registry estimate)

View Full Clinical Profile →

Discontinued / Inactive ctgov-meningococcal-b-rlp2086-vaccine-pfizer

meningococcal B rLP2086 vaccine

Target: Meningococcal disease

Platform: Biological (unspecified platform)

Key Milestone: Primary completion (most advanced trial): 2009-06 (registry estimate)

View Full Clinical Profile → Disease Hub →

Phase 1 Clinical Trial ctgov-20vpnc-pfizer

20vPnC

Target: Pneumococcal disease

Platform: Biological (unspecified platform)

Key Milestone: Primary completion (most advanced trial): 2027-05-14 (registry estimate)

View Full Clinical Profile → Disease Hub →

Phase 1 Clinical Trial ctgov-pg4-vaccine-in-buffer-1-with-low-dose-pa-001-pfizer

PG4 in Buffer 1 with low dose PA-002

Target: Pneumococcal disease

Platform: Biological (unspecified platform)

Key Milestone: Primary completion (most advanced trial): 2027-10-21 (registry estimate)

View Full Clinical Profile → Disease Hub →

Phase 2 Clinical Trial ctgov-c-difficile-vaccine-previously-studied-formulation-pfizer

C. difficile vaccine formulation 1.

Target: Clostridoides Difficile Associated Disease

Platform: Biological (unspecified platform)

Key Milestone: Primary completion (most advanced trial): 2031-06-19 (registry estimate)

View Full Clinical Profile →

Phase 2 Clinical Trial ctgov-vaccine-candidate-1-pfizer

TIV1 or TIV2

Target: Influenza

Platform: mRNA

Key Milestone: Primary completion (most advanced trial): 2027-06-22 (registry estimate)

View Full Clinical Profile → Disease Hub →

Phase 3 Clinical Trial ctgov-c-difficile-vaccine-pfizer

C.difficile vaccine

Target: Clostridioides Difficile Associated Disease

Platform: Biological (unspecified platform)

Key Milestone: Primary completion (most advanced trial): 2028-12-11 (registry estimate)

View Full Clinical Profile →

Phase 3 Clinical Trial ctgov-pg4-pfizer

PG4

Target: Pneumococcal disease

Platform: Biological (unspecified platform)

Key Milestone: Primary completion (most advanced trial): 2027-12-02 (registry estimate)

View Full Clinical Profile → Disease Hub →

Phase 3 Clinical Trial ctgov-rsvpref-pfizer

RSVpreF

Target: RSV

Platform: Biological (unspecified platform)

Key Milestone: Primary completion (most advanced trial): 2027-01-18 (registry estimate)

View Full Clinical Profile → Disease Hub →

Phase 3 Clinical Trial vla15

VLA15

Target: Lyme disease

Platform: Protein subunit (OspA)

Key Milestone: VALOR Phase 3 field efficacy results (company: H1 2026); BLA/MAA planned if positive

View Full Clinical Profile →

Explore Other Vaccine Developers & Sponsors

Compare pipeline volume, phase progression, and modalities across global biopharmaceutical manufacturers.

View All Vaccine Developers →